Toxicities and Outcome after CD19-directed Chimeric Antigen Receptor T-cell Therapy for Neurolymphomatosis (S29.010)

Authors

Institutions

Publication Details

Journal
Neurology
Published
2025-04-07
DOI
https://doi.org/10.1212/wnl.0000000000211257
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Toxicities and Outcome after CD19-directed Chimeric Antigen Receptor T-cell Therapy for Neurolymphomatosis (S29.010)

Jeremy S. Abramson, Sofia Doubrovinskaia, Philipp Karschnia, Leon D. Kaulen et al.
Neurology
CAR-T cell therapy research
article

Toxicities and Outcome after CD19-directed Chimeric Antigen Receptor T-cell Therapy for Neurolymphomatosis (S29.010)

Jeremy S. Abramson, Sofia Doubrovinskaia, Philipp Karschnia, Leon D. Kaulen, Jörg Dietrich, María Martínez-Lage, Matthew J. Frigault, Wolfgang Wick, Ganesh M. Shankar
article en

Abstract

No abstract available for this paper.
NeurologyVol. 104(7_Supplement_1)
Harvard University (US), Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), Heidelberg University (DE), Massachusetts General Hospital (US), Neurology, Inc (US)
Good health and well-being
Openalex Percentile: Top 90%
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.